Ignite Creation Date:
2024-05-06 @ 6:19 PM
Last Modification Date:
2024-10-26 @ 2:45 PM
Study NCT ID:
NCT05620706
Status:
RECRUITING
Last Update Posted:
2022-11-22
First Post:
2022-11-11
Brief Title:
Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
Sponsor:
Shenzhen University General Hospital
Organization:
Shenzhen University General Hospital
Study Overview
Official Title:
Study of GPC-3 CAR-T Cells in Advanced Hepatocellular Carcinoma
Status:
RECRUITING
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hepatocellular carcinoma is a highly heterogeneous disease Treatment strategies for advanced hepatocellular carcinoma are limited Phosphatidylinositol proteoglycan 3 GPC3 is a heparan sulfate glycoprotein HSPG on the surface of the cell membrane It is highly expressed in liver cancer tissues but hardly expressed in normal liver tissues It is an ideal target for tumor treatment Investigators aimed to test the safety and efficacy of GPC3 CAR-T cells in patients with advanced hepatocellular carcinoma
Detailed Description:
Hepatocellular carcinoma is a highly heterogeneous disease Treatment strategies for advanced hepatocellular carcinoma are limited Resulting in a poor prognosis Phosphatidylinositol proteoglycan 3 GPC3 is a heparan sulfate glycoprotein HSPG on the surface of the cell membrane It is highly expressed in liver cancer tissues but hardly expressed in normal liver tissues It is an ideal target for tumor treatment Investigators aimed to test the safety and efficacy of GPC3 CAR-T cells in patients with advanced hepatocellular carcinoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None